Alan Boobis

List of Publications by Year in Descending Order

257 papers	13,089 citations	66 h-index	103 g-index
293 ext. papers	14,238 ext. citations	5.2 avg, IF	5.92 L-index

#	Paper	IF	Citations
257	Methyl-tert-butyl ether (MTBE): integration of rat and mouse carcinogenicity data with mode of action and human and rodent bioassay dosimetry and toxicokinetics indicates MTBE is not a plausible human carcinogen.. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2022**, 1-27	8.6	
256	Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment. *Regulatory Toxicology and Pharmacology*, **2021**, 127, 105070	3.4	4
255	Characterising vaping products in the United Kingdom: an analysis of Tobacco Products Directive notification data. *Addiction*, **2021**, 116, 2521-2528	4.6	1
254	INDUSTRIAL PERSPECTIVES **2020**, 127-147		
253	Hazard identification, classification, and risk assessment of carcinogens: too much or too little? - Report of an ECETOC workshop. *Critical Reviews in Toxicology*, **2020**, 50, 72-95	5.7	4
252	Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2020**, 83, 485-494	3.2	7
251	An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. *Regulatory Toxicology and Pharmacology*, **2020**, 112, 104592	3.4	46
250	Relevance of mouse lung tumors to human risk assessment. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2020**, 23, 214-241	8.6	11
249	Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits. *Regulatory Toxicology and Pharmacology*, **2020**, 116, 104734	3.4	5
248	Value and limitation of bioassays to support the application of the threshold of toxicological concern to prioritise unidentified chemicals in food contact materials. *Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment*, **2019**, 36, 1903-1936	3.2	11
247	Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible. *Regulatory Toxicology and Pharmacology*, **2019**, 103, 124-129	3.4	30
246	A mode-of-action ontology model for safety evaluation of chemicals: Outcome of a series of workshops on repeated dose toxicity. *Toxicology in Vitro*, **2019**, 59, 44-50	3.6	13
245	Harmonized methodology to assess chronic dietary exposure to residues from compounds used as pesticide and veterinary drug. *Critical Reviews in Toxicology*, **2019**, 49, 1-10	5.7	5
244	Characterizing the coverage of critical effects relevant in the safety evaluation of food additives by AOPs. *Archives of Toxicology*, **2019**, 93, 2115-2125	5.8	10
243	Risk Benefit Assessment of foods: Key findings from an international workshop. *Food Research International*, **2019**, 116, 859-869	7	20
242	Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans. *Regulatory Toxicology and Pharmacology*, **2019**, 103, 100-105	3.4	42
241	Chemical carcinogenicity revisited 1: A unified theory of carcinogenicity based on contemporary knowledge. *Regulatory Toxicology and Pharmacology*, **2019**, 103, 86-92	3.4	39

240	Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. *Toxicology Research*, **2018**, 7, 347-357	2.6	41
239	Building a developmental toxicity ontology. *Birth Defects Research*, **2018**, 110, 502-518	2.9	21
238	Benchmark dose (BMD) modeling: current practice, issues, and challenges. *Critical Reviews in Toxicology*, **2018**, 48, 387-415	5.7	73
237	Human relevance of rodent liver tumors: Key insights from a Toxicology Forum workshop on nongenotoxic modes of action. *Regulatory Toxicology and Pharmacology*, **2018**, 92, 1-7	3.4	36
236	Response to Loomis et al Comment on Boobis et al. *Regulatory Toxicology and Pharmacology*, **2017**, 88, 358-359	3.4	1
235	IARC use of oxidative stress as key mode of action characteristic for facilitating cancer classification: Glyphosate case example illustrating a lack of robustness in interpretative implementation. *Regulatory Toxicology and Pharmacology*, **2017**, 86, 157-166	3.4	14
234	Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation. *Critical Reviews in Toxicology*, **2017**, 47, 705-727	5.7	27
233	Improving selection of markers in nutrition research: evaluation of the criteria proposed by the ILSI Europe Marker Validation Initiative. *Nutrition Research Reviews*, **2017**, 30, 73-81	7	3
232	Thresholds of Toxicological Concern for cosmetics-related substances: New database, thresholds, and enrichment of chemical space. *Food and Chemical Toxicology*, **2017**, 109, 170-193	4.7	64
231	The dose makes the poison Key implications for mode of action (mechanistic) research in a 21st century toxicology paradigm. *Current Opinion in Toxicology*, **2017**, 3, 87-91	4.4	19
230	Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance. *Critical Reviews in Toxicology*, **2017**, 47, 729-749	5.7	39
229	How well can carcinogenicity be predicted by high throughput "characteristics of carcinogens" mechanistic data?. *Regulatory Toxicology and Pharmacology*, **2017**, 90, 185-196	3.4	29
228	Characterizing chronic and acute health risks of residues of veterinary drugs in food: latest methodological developments by the joint FAO/WHO expert committee on food additives. *Critical Reviews in Toxicology*, **2017**, 47, 885-899	5.7	18
227	A framework for cumulative risk assessment in the 21st century. *Critical Reviews in Toxicology*, **2017**, 47, 85-97	5.7	38
226	Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement. *Archives of Toxicology*, **2017**, 91, 1001-1006	5.8	86
225	Upholding science in health, safety and environmental risk assessments and regulations. *Toxicology*, **2016**, 371, 12-16	4.4	5
224	Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society. *Regulatory Toxicology and Pharmacology*, **2016**, 82, 158-166	3.4	51
223	Considering new methodologies in strategies for safety assessment of foods and food ingredients. *Food and Chemical Toxicology*, **2016**, 91, 19-35	4.7	43

222	Effects of mid-respiratory chain inhibition on mitochondrial function and. *Toxicology Research*, **2016**, 5, 136-150	2.6	7
221	Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. *Oncotarget*, **2016**, 7, 44505-44521	3.3	16
220	Problem formulation for risk assessment of combined exposures to chemicals and other stressors in humans. *Critical Reviews in Toxicology*, **2016**, 46, 835-844	5.7	24
219	E2F1-mediated FOS induction in arsenic trioxide-induced cellular transformation: effects of global H3K9 hypoacetylation and promoter-specific hyperacetylation in vitro. *Environmental Health Perspectives*, **2015**, 123, 484-92	8.4	10
218	Risk assessments for chronic exposure of children and prospective parents to ethylbenzene (CAS No. 100-41-4). *Critical Reviews in Toxicology*, **2015**, 45, 662-726	5.7	4
217	Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure?. *Regulatory Toxicology and Pharmacology*, **2015**, 73, 737-46	3.4	11
216	Towards microbial fermentation metabolites as markers for health benefits of prebiotics. *Nutrition Research Reviews*, **2015**, 28, 42-66	7	173
215	Adverse Outcome Pathways can drive non-animal approaches for safety assessment. *Journal of Applied Toxicology*, **2015**, 35, 971-5	4.1	66
214	PGC-1 controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity. *Aging*, **2015**, 7, 629-47	5.6	57
213	The role of hazard- and risk-based approaches in ensuring food safety. *Trends in Food Science and Technology*, **2015**, 46, 176-188	15.3	54
212	Human health screening level risk assessments of tertiary-butyl acetate (TBAC): calculated acute and chronic reference concentration (RfC) and Hazard Quotient (HQ) values based on toxicity and exposure scenario evaluations. *Critical Reviews in Toxicology*, **2015**, 45, 142-71	5.7	5
211	Systems toxicology: from basic research to risk assessment. *Chemical Research in Toxicology*, **2014**, 27, 314-29	4	236
210	Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and derivation of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: considerations of biological relevance of tumour type, data quality and uncertainty assessment. *Food and Chemical Toxicology*, **2014**, 70, 264-89	4.7	19
209	Risk assessment in the 21st century: roadmap and matrix. *Critical Reviews in Toxicology*, **2014**, 44 Suppl 3, 6-16	5.7	78
208	Instruments for assessing risk of bias and other methodological criteria of animal studies: omission of well-established methods. *Environmental Health Perspectives*, **2014**, 122, A66-7	8.4	1
207	A 21st century roadmap for human health risk assessment. *Critical Reviews in Toxicology*, **2014**, 44 Suppl 3, 1-5	5.7	70
206	The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events. *Critical Reviews in Toxicology*, **2014**, 44 Suppl 3, 17-43	5.7	54
205	New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. *Journal of Applied Toxicology*, **2014**, 34, 1-18	4.1	188

204	Establishing the level of safety concern for chemicals in food without the need for toxicity testing. *Regulatory Toxicology and Pharmacology*, **2014**, 68, 275-96	3.4	37
203	A framework for fit-for-purpose dose response assessment. *Regulatory Toxicology and Pharmacology*, **2013**, 66, 234-40	3.4	11
202	Global food supply. Reevaluate pesticides for food security and safety. *Science*, **2013**, 341, 717-8	33.3	96
201	An F1-extended one-generation reproductive toxicity study in Crl:CD(SD) rats with 2,4-dichlorophenoxyacetic acid. *Toxicological Sciences*, **2013**, 136, 527-47	4.4	30
200	Interpretation of the margin of exposure for genotoxic carcinogens - elicitation of expert knowledge about the form of the dose response curve at human relevant exposures. *Food and Chemical Toxicology*, **2013**, 57, 106-18	4.7	9
199	Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans. *Food and Chemical Toxicology*, **2013**, 60, 550-62	4.7	21
198	Critical appraisal of the assessment of benefits and risks for foods, 'BRAFO Consensus Working Group'. *Food and Chemical Toxicology*, **2013**, 55, 659-75	4.7	25
197	Life-stage-, sex-, and dose-dependent dietary toxicokinetics and relationship to toxicity of 2,4-dichlorophenoxyacetic acid (2,4-D) in rats: implications for toxicity test dose selection, design, and interpretation. *Toxicological Sciences*, **2013**, 136, 294-307	4.4	28
196	Elucidation of toxicity pathways in lung epithelial cells induced by silicon dioxide nanoparticles. *PLoS ONE*, **2013**, 8, e72363	3.7	34
195	Use of toxicokinetics to support chemical evaluation: Informing high dose selection and study interpretation. *Regulatory Toxicology and Pharmacology*, **2012**, 62, 241-7	3.4	36
194	Assessment of diurnal systemic dose of agrochemicals in regulatory toxicity testing--an integrated approach without additional animal use. *Regulatory Toxicology and Pharmacology*, **2012**, 63, 321-32	3.4	44
193	BRAFO tiered approach for Benefit-Risk Assessment of Foods. *Food and Chemical Toxicology*, **2012**, 50 Suppl 4, S684-98	4.7	42
192	Miscellaneous Chlorinated Hydrocarbon Pesticides **2012**, 429-469		
191	Risk assessment of contaminants in food and feed. *EFSA Journal*, **2012**, 10, s1004	2.3	40
190	Application of the TTC concept to unknown substances found in analysis of foods. *Food and Chemical Toxicology*, **2011**, 49, 1643-60	4.7	34
189	Managing the challenge of chemically reactive metabolites in drug development. *Nature Reviews Drug Discovery*, **2011**, 10, 292-306	64.1	348
188	Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. *Regulatory Toxicology and Pharmacology*, **2011**, 60, S1-S1	3.4	190
187	Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. *Archives of Toxicology*, **2011**, 85, 367-485	5.8	398

186	Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview. *Critical Reviews in Toxicology*, **2011**, 41, 175-86	5.7	44
185	A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens. *Critical Reviews in Toxicology*, **2011**, 41, 507-44	5.7	36
184	Critical analysis of literature on low-dose synergy for use in screening chemical mixtures for risk assessment. *Critical Reviews in Toxicology*, **2011**, 41, 369-83	5.7	109
183	Guidance for the classification of carcinogens under the Globally Harmonised System of Classification and Labelling of Chemicals (GHS). *Critical Reviews in Toxicology*, **2010**, 40, 245-85	5.7	14
182	Mode of action considerations in the quantitative assessment of tumour responses in the liver. *Basic and Clinical Pharmacology and Toxicology*, **2010**, 106, 173-9	3.1	7
181	Authors response to Huff et al., Clarifying carcinogenicity of ethylbenzene *Regulatory Toxicology and Pharmacology*, **2010**, 58, 170-172	3.4	
180	Application of key events analysis to chemical carcinogens and noncarcinogens. *Critical Reviews in Food Science and Nutrition*, **2009**, 49, 690-707	11.5	80
179	Fate and occurrence of alkylphenolic compounds in sewage sludges determined by liquid chromatography tandem mass spectrometry. *Environmental Technology (United Kingdom)*, **2009**, 30, 1415-24	2.6	8
178	A data-based assessment of alternative strategies for identification of potential human cancer hazards. *Toxicologic Pathology*, **2009**, 37, 714-32	2.1	40
177	The Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds. *Critical Reviews in Food Science and Nutrition*, **2009**, 49, 682-9	11.5	77
176	Increased expression of histone proteins during estrogen-mediated cell proliferation. *Environmental Health Perspectives*, **2009**, 117, 928-34	8.4	21
175	The significance of sample mass in the analysis of steroid estrogens in sewage sludges and the derivation of partition coefficients in wastewaters. *Journal of Chromatography A*, **2009**, 1216, 4923-6	4.5	18
174	Influence of operating parameters on the biodegradation of steroid estrogens and nonylphenolic compounds during biological wastewater treatment processes. *Environmental Science & Technology*, **2009**, 43, 6646-54	10.3	81
173	Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models. *Expert Opinion on Therapeutic Targets*, **2009**, 13, 867-87	6.4	6
172	Critical analysis of literature on low dose synergy for use of TTC in screening chemical mixtures for risk assessment. *Toxicology Letters*, **2009**, 189, S51	4.4	2
171	Drug interactions. *Drug Metabolism Reviews*, **2009**, 41, 486-527	7	41
170	Cumulative risk assessment of pesticide residues in food. *Toxicology Letters*, **2008**, 180, 137-50	4.4	190
169	Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity). *Toxicology Letters*, **2008**, 181, 93-103	4.4	7

168	Treatment and removal strategies for estrogens from wastewater. *Environmental Technology (United Kingdom)*, **2008**, 29, 245-67	2.6	104
167	A sensitive and robust method for the determination of alkylphenol polyethoxylates and their carboxylic acids and their transformation in a trickling filter wastewater treatment plant. *Chemosphere*, **2008**, 73, 551-6	8.4	25
166	IPCS framework for analyzing the relevance of a noncancer mode of action for humans. *Critical Reviews in Toxicology*, **2008**, 38, 87-96	5.7	271
165	Local kinetics and dynamics of xenobiotics. *Critical Reviews in Toxicology*, **2008**, 38, 697-720	5.7	34
164	Re: Guyton, Kathryn Z., Barone, Stanley, Jr., Brown, Rebecca C., Euling, Susan Y., Jinot, Jennifer, Makris, Susan (2008). Mode of action frameworks: a critical analysis. Journal of Toxicology and Environmental Health, Part B, 11(1): 16-31. *Journal of Toxicology and Environmental Health - Part B: Critical Reviews*, **2008**, 11, 681-3; author reply 684-5	8.6	7
163	Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. *Environmental Health Perspectives*, **2008**, 116, 149-57	8.4	84
162	Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis. *Ciencia E Saude Coletiva*, **2008**, 13, 1601-18	2.2	10
161	Defective Spermatogenesis: Martin et al. Respond. *Environmental Health Perspectives*, **2008**, 116,	8.4	78
160	Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics. *Proteomics*, **2008**, 8, 1987-2005	4.8	21
159	Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. *ATLA Alternatives To Laboratory Animals*, **2007**, 35, 661-71	2.1	46
158	Determination of steroid estrogens in wastewater by high performance liquid chromatography-tandem mass spectrometry. *Journal of Chromatography A*, **2007**, 1173, 81-7	4.5	92
157	C-terminal antibodies (CTAbs): a simple and broadly applicable approach for the rapid generation of protein-specific antibodies with predefined specificity. *Proteomics*, **2007**, 7, 1364-72	4.8	6
156	Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. *Basic and Clinical Pharmacology and Toxicology*, **2007**, 100, 240-8	3.1	25
155	Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. *Current Drug Metabolism*, **2007**, 8, 33-45	3.5	349
154	Human health and endocrine disruption: a simple multicriteria framework for the qualitative assessment of end point specific risks in a context of scientific uncertainty. *Toxicological Sciences*, **2007**, 98, 332-47	4.4	27
153	Searching for novel biomarkers of centrally and peripehrally-acting neurotoxicants, using surface-enhanced laser desorption/ionisation-time-of-flight mass spectrometry (SELDI-TOF MS). *Food and Chemical Toxicology*, **2007**, 45, 2126-37	4.7	2
152	Risk assessment of dietary supplements. *Novartis Foundation Symposium*, **2007**, 282, 3-25; discussion 25-8, 212-8		4
151	Strategies to assess systemic exposure of chemicals in subchronic/chronic diet and drinking water studies. *Toxicology and Applied Pharmacology*, **2006**, 211, 245-60	4.6	54

150	Evidence for genotoxicity of pesticides in pesticide applicators: a review. *Mutagenesis*, **2006**, 21, 93-103	2.8	80
149	4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS Human Relevance Framework for Analysis of a cancer mode of action for humans. *Critical Reviews in Toxicology*, **2006**, 36, 803-19	5.7	39
148	Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS Human Relevance Framework for analysis of a cancer mode of action. *Critical Reviews in Toxicology*, **2006**, 36, 793-801	5.7	49
147	Mode of action in relevance of rodent liver tumors to human cancer risk. *Toxicological Sciences*, **2006**, 89, 51-6	4.4	220
146	IPCS framework for analyzing the relevance of a cancer mode of action for humans. *Critical Reviews in Toxicology*, **2006**, 36, 781-92	5.7	361
145	A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. *Critical Reviews in Toxicology*, **2006**, 36, 37-68	5.7	70
144	Agricultural chemical safety assessment: A multisector approach to the modernization of human safety requirements. *Critical Reviews in Toxicology*, **2006**, 36, 1-7	5.7	45
143	Assessment of uncertainty in a probabilistic model of consumer exposure to pesticide residues in food. *Food Additives and Contaminants*, **2006**, 23, 601-15		13
142	Use of protein profiles to characterise concentration-effect curves of mixtures of estrogenic compounds in human breast cell lines. *Toxicology Letters*, **2006**, 164, S165-S166	4.4	3
141	IPCS framework for analysing the relevance of a cancer mode of action for humans. *Toxicology Letters*, **2006**, 164, S254-S255	4.4	4
140	Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. *Pharmaceutical Research*, **2006**, 23, 533-9	4.5	59
139	Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. *Cancer Causes and Control*, **2006**, 17, 759-70	2.8	185
138	An approach to investigating the importance of high potency polycyclic aromatic hydrocarbons (PAHs) in the induction of lung cancer by air pollution. *Food and Chemical Toxicology*, **2005**, 43, 1103-16	4.7	123
137	Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003. *Toxicology Letters*, **2005**, 156, 227-40	4.4	23
136	CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. *Pharmacogenetics and Genomics*, **2005**, 15, 625-31	1.9	75
135	Genetic and other sources of variation in the activity of serum paraoxonase/diazoxonase in humans: consequences for risk from exposure to diazinon. *Pharmacogenetics and Genomics*, **2005**, 15, 51-60	1.9	30
134	Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. *British Journal of Clinical Pharmacology*, **2005**, 60, 107-12	3.8	165
133	Positron emission tomography in the quantification of cellular and biochemical responses to intrapulmonary particulates. *Toxicology and Applied Pharmacology*, **2005**, 207, 230-6	4.6	11

132	Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans. *Carcinogenesis*, **2004**, 25, 1659-69	4.6	72
131	Urinary N2-(2'-deoxyguanosin-8-yl)PhIP as a biomarker for PhIP exposure. *Carcinogenesis*, **2004**, 25, 1053-62	4.6	6
130	Dose-dependent transitions in mechanisms of toxicity. *Toxicology and Applied Pharmacology*, **2004**, 201, 203-25	4.6	137
129	Dose-dependent transitions in mechanisms of toxicity: case studies. *Toxicology and Applied Pharmacology*, **2004**, 201, 226-94	4.6	141
128	Approaches to carcinogenic risk assessment for polycyclic aromatic hydrocarbons: a UK perspective. *Regulatory Toxicology and Pharmacology*, **2004**, 40, 54-66	3.4	101
127	A strategy for investigating the CYP superfamily using targeted antibodies is a paradigm for functional genomic studies. *Drug Metabolism and Disposition*, **2003**, 31, 1476-80	4	13
126	Differential expression of cytochrome P450 enzymes in cultured and intact foetal rat ventral mesencephalon. *Journal of Neural Transmission*, **2003**, 110, 1091-101	4.3	3
125	Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. *British Journal of Clinical Pharmacology*, **2003**, 55, 68-76	3.8	134
124	Expression of CYP3A4 in human breast tumour and non-tumour tissues. *Cancer Letters*, **2003**, 202, 17-23	9.9	29
123	Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. *Drug Metabolism and Disposition*, **2003**, 31, 755-61	4	196
122	Risk characterisation of chemicals in food and diet. *Food and Chemical Toxicology*, **2003**, 41, 1211-71	4.7	147
121	Immunohistochemical demonstration of the expression of CYP2E1 in human breast tumour and non-tumour tissues. *Cancer Letters*, **2003**, 196, 153-9	9.9	28
120	Adduction of the chloroform metabolite phosgene to lysine residues of human histone H2B. *Chemical Research in Toxicology*, **2003**, 16, 266-75	4	23
119	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. *Drug Metabolism and Disposition*, **2003**, 31, 1093-102	4	72
118	Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. *Drug Metabolism and Disposition*, **2003**, 31, 282-8	4	84
117	Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. *Toxicology and Applied Pharmacology*, **2002**, 183, 46-54	4.6	28
116	Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. *British Journal of Cancer*, **2002**, 86, 1052-6	8.7	14
115	The mutational signature of alpha-hydroxytamoxifen at Hprt locus in Chinese hamster cells. *Carcinogenesis*, **2002**, 23, 1947-52	4.6	2

114	Current knowledge and recent developments in consumer exposure assessment of pesticides: a UK perspective. *Food Additives and Contaminants*, **2002**, 19, 837-52		20
113	Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. *Xenobiotica*, **2002**, 32, 505-20	2	304
112	Expression of P450 enzymes in rat whole skin and cultured epidermal keratinocytes. *Biochemical and Biophysical Research Communications*, **2002**, 297, 65-70	3.4	26
111	Methods of in vitro toxicology. *Food and Chemical Toxicology*, **2002**, 40, 193-236	4.7	322
110	Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. *Neonatology*, **2001**, 80, 193-201	4	58
109	Diazinon is activated by CYP2C19 in human liver. *Toxicology and Applied Pharmacology*, **2001**, 177, 68-76	4.6	79
108	In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. *European Journal of Clinical Pharmacology*, **2001**, 57, 621-9	2.8	49
107	Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies. *BBA - Proteins and Proteomics*, **2001**, 1546, 143-55		16
106	Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. *Xenobiotica*, **2001**, 31, 321-43	2	51
105	Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. *Xenobiotica*, **2001**, 31, 135-51	2	9
104	Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. *Carcinogenesis*, **2001**, 22, 1413-20	4.6	70
103	Adducts of the chloroform metabolite phosgene. *Advances in Experimental Medicine and Biology*, **2001**, 500, 129-32	3.6	2
102	Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. *International Journal of Cancer*, **2000**, 86, 610-6	7.5	69
101	Expression and distribution of CYP2C enzymes in rat basal ganglia. *Synapse*, **2000**, 38, 392-402	2.4	14
100	Mass spectrometric detection and measurement of N2-(2'-deoxyguanosin-8-yl)PhIP adducts in DNA. *Biomedical Applications*, **2000**, 744, 55-64		18
99	The mutagenicity of benzo[a]pyrene in mouse small intestine. *Carcinogenesis*, **1999**, 20, 109-14	4.6	30
98	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. *Biochemical Pharmacology*, **1999**, 58, 787-96	6	188
97	Expression and localisation of CYP2D enzymes in rat basal ganglia. *Brain Research*, **1999**, 822, 175-91	3.7	24

96	Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. *Pharmacogenetics and Genomics*, **1999**, 9, 357-66		48
95	Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans. *Biochemical Pharmacology*, **1998**, 56, 377-87	6	117
94	Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. *Neuroscience*, **1998**, 86, 511-9	3.9	66
93	Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. *Respiratory Medicine*, **1998**, 92 Suppl B, 2-6	4.6	33
92	Pulmonary fibrosis correlates with duration of tissue neutrophil activation. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 620-8	10.2	92
91	Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. *Xenobiotica*, **1998**, 28, 493-506	2	20
90	Genetic analysis of PHIP intestinal mutations in MutaMouse. *Mutagenesis*, **1998**, 13, 601-5	2.8	31
89	Analysis of the N-(deoxyguanosin-8-yl) adduct of the food derived carcinogen PhIP using capillary electrophoresis. *Biochemical Society Transactions*, **1997**, 25, 27S	5.1	
88	Evidence for nitric oxide participation in down-regulation of CYP2B1/2 gene expression at the pretranslational level. *Toxicology Letters*, **1997**, 90, 207-16	4.4	32
87	Specific inhibition of human CYP1A2 using a targeted antibody. *Biochemical Pharmacology*, **1997**, 54, 189-97	6	6
86	Expression and localization of CYP3A4 and CYP3A5 in human lung. *American Journal of Respiratory Cell and Molecular Biology*, **1997**, 16, 242-9	5.7	123
85	Assessing human risk to heterocyclic amines. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1997**, 376, 53-60	3.3	26
84	The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. *European Journal of Clinical Pharmacology*, **1997**, 52, 311-5	2.8	56
83	Expression and inducibility of P450 enzymes during liver ontogeny. *Microscopy Research and Technique*, **1997**, 39, 424-35	2.8	65
82	Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. *Biochemical Pharmacology*, **1996**, 51, 403-11	6	182
81	Interindividual variability in metabolic activation in humans in vivo. *Environmental Toxicology and Pharmacology*, **1996**, 2, 161-3	5.8	1
80	Brain cytochrome P450 in the rat. *Biochemical Society Transactions*, **1996**, 24, 52S	5.1	2
79	Selective localisation of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using anti-peptide antisera. *Brain Research*, **1996**, 743, 324-8	3.7	48

78	Dissecting the function of cytochrome P450. *British Journal of Clinical Pharmacology*, **1996**, 42, 81-9	3.8	17
77	Developmental changes in hepatic activation of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in rabbit. *Carcinogenesis*, **1996**, 17, 555-8	4.6	3
76	Mutational spectra of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine(PhIP) at the Chinese hamsters hprt locus. *Carcinogenesis*, **1996**, 17, 617-24	4.6	67
75	Enzymic and interindividual differences in the human metabolism of heterocyclic amines. *Archives of Toxicology Supplement*, **1996**, 18, 286-302		12
74	Exposure to and activation of dietary heterocyclic amines in humans. *Critical Reviews in Oncology/Hematology*, **1995**, 21, 19-31	7	16
73	Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. *Biochemical Pharmacology*, **1995**, 49, 39-47	6	46
72	Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. *Biochemical Pharmacology*, **1995**, 50, 2047-56	6	88
71	Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. *Carcinogenesis*, **1994**, 15, 829-36	4.6	124
70	The role of CYP1A enzymes in murine activation of the cooked food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Biochemical Society Transactions*, **1994**, 22, 128S	5.1	
69	Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP. *Carcinogenesis*, **1993**, 14, 585-92	4.6	67
68	An inhibitory monoclonal anti-protein antibody and an anti-peptide antibody share an epitope on rat cytochrome P-450 enzymes CYP1A1 and CYP1A2. *BBA - Proteins and Proteomics*, **1993**, 1161, 38-46		8
67	Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. *Biochemical Pharmacology*, **1993**, 46, 213-20	6	29
66	N-hydroxy-MeIQx is the major microsomal oxidation product of the dietary carcinogen MeIQx with human liver. *Carcinogenesis*, **1992**, 13, 2221-6	4.6	47
65	Molecular basis for differences in susceptibility to toxicants: introduction. *Toxicology Letters*, **1992**, 64-65 Spec No, 109-13	4.4	4
64	Identification of the epitope of a monoclonal antibody which binds to several cytochromes P450 in the CYP1A subfamily. *Biochemical Pharmacology*, **1992**, 43, 1737-46	6	8
63	Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. *Biochemical Pharmacology*, **1992**, 43, 1876-9	6	53
62	Paracetamol toxicity in hamster isolated hepatocytes: the increase in cytosolic calcium accompanies, rather than precedes, loss of viability. *Archives of Toxicology*, **1992**, 66, 408-12	5.8	16
61	Antipeptide antibodies in studies of cytochromes P450IA. *Methods in Enzymology*, **1991**, 206, 220-33	1.7	20

60	Combined assay for phenacetin and paracetamol in plasma using capillary column gas chromatography-negative-ion mass spectrometry. *Biomedical Applications*, **1991**, 568, 341-50		20
59	Rapid analysis for metabolites of 11C-labelled drugs: fate of [11C]-S-4-(tert.-butylamino-2-hydroxypropoxy)-benzimidazol-2-one in the dog. *Biomedical Applications*, **1991**, 570, 361-70		19
58	Mechanisms of cell death. *Archives of Toxicology*, **1991**, 65, 437-44	5.8	154
57	Orientation of cytochromes P450 in the endoplasmic reticulum. *Biochemistry*, **1991**, 30, 71-6	3.2	73
56	Assay of caffeine metabolism in vitro by human liver microsomes using radio-high-performance liquid chromatography. *Journal of Pharmaceutical and Biomedical Analysis*, **1990**, 8, 783-7	3.5	7
55	Mechanisms of cell toxicity. *Current Opinion in Cell Biology*, **1990**, 2, 231-7	9	18
54	Evidence for a direct role of intracellular calcium in paracetamol toxicity. *Biochemical Pharmacology* , **1990**, 39, 1277-81	6	45
53	High affinity phenacetin O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. *Biochemical Pharmacology*, **1990**, 39, 489-98	6	49
52	The inducibility and catalytic activity of cytochromes P450c (P450IA1) and P450d (P450IA2) in rat tissues. *Biochemical Pharmacology*, **1990**, 39, 499-506	6	68
51	Rapid tolerance to the hypotensive effects of glyceryl trinitrate in the rat: prevention by N-acetyl-L- but not N-acetyl-D-cysteine. *British Journal of Pharmacology*, **1990**, 99, 825-9	8.6	28
50	The Effects of Trimethadione and Its Metabolite on Human Liver Debrisoquine 4-Hydroxylase Activity In Vitro. *The Showa University Journal of Medical Sciences*, **1990**, 2, 27-30	0.1	
49	Cross-reaction of antibodies to coupling groups used in the production of anti-peptide antibodies. *Journal of Immunological Methods*, **1989**, 117, 215-20	2.5	22
48	Identification and location of alpha-helices in mammalian cytochromes P450. *Biochemistry*, **1989**, 28, 3762-70	3.2	83
47	The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. *Biochemical Pharmacology*, **1989**, 38, 2795-9	6	109
46	Immunohistochemical localization of cytochrome P450b/e in hepatic and extrahepatic tissues of the rat. *Biochemical Pharmacology*, **1989**, 38, 3305-22	6	52
45	Antibodies against rat cytochrome P-450d: comparison of the purified protein and a synthetic peptide as immunogens. *Biochemical Society Transactions*, **1989**, 17, 535-536	5.1	
44	3,8-Dimethyl-2-nitro-imidazo[4,5-f]quinoxaline(Nitro-MeIQx) is a potent direct-acting mutagen. *Biochemical Society Transactions*, **1989**, 17, 540-541	5.1	
43	Activation of the food carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline by hepatocytes. *Biochemical Society Transactions*, **1989**, 17, 734-735	5.1	2

42	Species differences in specificity of hydrocarbon-inducible forms of cytochrome P-450. *Biochemical Society Transactions*, **1989**, 17, 1021-2	5.1	1
41	Identification of surface regions of cytochromes P-450 using anti-peptide antibodies. *Biochemical Society Transactions*, **1989**, 17, 1022-3	5.1	2
40	Ontogeny of expression, inducibility and distribution of cytochromes P-450 forms 4 and 6 in rabbit liver. *Biochemical Society Transactions*, **1989**, 17, 1023-4	5.1	3
39	Determination of the N-acetyl metabolites of 4,4'-methylene dianiline and 4,4'-methylene-bis(2-chloroaniline) in urine. *Biological Mass Spectrometry*, **1988**, 17, 161-7		39
38	Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat. *Biochemical Pharmacology*, **1988**, 37, 3735-41	6	38
37	Hepatotoxicity of carbon tetrachloride: protection by pretreatment of mice with polyriboinosinic acid polyribocytidylic acid. *Biochemical Society Transactions*, **1988**, 16, 632-633	5.1	
36	Cytoprotective effects of 16,16-dimethyl prostaglandin E2 on paracetamol toxicity in isolated hepatocytes. *Biochemical Society Transactions*, **1988**, 16, 641-642	5.1	2
35	Immunohistochemical localization of cytochrome P-450 b/e in hepatic and extrahepatic rat tissues. *Biochemical Society Transactions*, **1988**, 16, 642-643	5.1	2
34	Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite. *Biochemical Pharmacology*, **1987**, 36, 1041-52	6	74
33	Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?. *Archives of Toxicology*, **1986**, 58, 165-70	5.8	6
32	Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors. *Biochemical Pharmacology*, **1986**, 35, 2961-5	6	29
31	Immunocytochemical localization of cytochrome P-450 in hepatic and extra-hepatic tissues of the rat with a monoclonal antibody against cytochrome P-450 c. *Biochemical Pharmacology*, **1986**, 35, 4543-54	6	108
30	The metabolic activation of 4,4'-methylene-bis-(2-chlorobenzeneamine) to a bacterial mutagen by hepatic postmitochondrial supernatant from human and other species. *Environmental Mutagenesis*, **1985**, 7, 501-9		4
29	Polymorphic metabolism of the carcinogen 2-acetylaminofluorene in human liver microsomes. *Carcinogenesis*, **1985**, 6, 1721-4	4.6	34
28	Antipyrine elimination in patients with obstructive jaundice: a predictor of outcome. *American Journal of Surgery*, **1985**, 149, 140-3	2.7	23
27	Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. *Biochemical Pharmacology*, **1985**, 34, 65-71	6	64
26	A monoclonal antibody raised to rat liver cytochrome P-448 (form C) which recognises an epitope common to many other forms of cytochrome P-450. *Biochemical Pharmacology*, **1985**, 34, 1671-81	6	24
25	Species differences in the hepatic formation of green pigments following the administration of norethindrone. *Biochemical Pharmacology*, **1984**, 33, 459-64	6	5

24	Multiple forms of human cytochrome P-450. *Biochemical Society Transactions*, **1984**, 12, 78-80	5.1	6
23	Interindividual Differences in Monooxygenase Activities of Human Liver **1984**, 109-153		1
22	Effect of rifampicin and isoniazid on vitamin D metabolism. *Clinical Pharmacology and Therapeutics*, **1982**, 32, 525-30	6.1	86
21	Immunopurification of cytochrome P-448 from microsomal fractions of rabbit liver with retention of metabolic activity. *Biochemical Pharmacology*, **1982**, 31, 1815-7	6	15
20	Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. *Biochemical Pharmacology*, **1981**, 30, 2451-6	6	77
19	The selective activation of cytochrome P-450 dependent microsomal hydroxylases in human and rat liver microsomes. *Biochemical Pharmacology*, **1981**, 30, 1702-3	6	19
18	Differential induction of antipyrine metabolism by rifampicin. *European Journal of Clinical Pharmacology*, **1981**, 21, 155-60	2.8	70
17	Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. *Clinical Pharmacology and Therapeutics*, **1981**, 30, 363-7	6.1	57
16	Paracetamol oxidation: synthesis and reactivity of N-acetyl-p-benzoquinoneimine. *Tetrahedron Letters*, **1980**, 21, 4947-4950	2	48
15	Stereoselective excretion of (3-methoxy-4-sulphooxyphenyl)ethylene glycol (MHPG sulphate) in the dog. *Naunyn-Schmiedebergfs Archives of Pharmacology*, **1980**, 314, 89-96	3.4	6
14	DNA binding of benzo[a]pyrene metabolites. Effects of substrate and microsomal protein concentration in vitro, dietary contaminants, and tissue differences. *Pharmacology*, **1980**, 20, 137-48	2.3	14
13	Catecholamine turnover in essential hypertension. *Clinical and Experimental Hypertension*, **1980**, 2, 395-408		7
12	Drug oxidation in Asian vegetarians. *Lancet, The*, **1980**, 2, 151	40	10
11	Effects of microsomal enzyme inducers in vivo and inhibitors in vitro on the covalent binding of benzo[a]pyrene metabolites to DNA catalyzed by liver microsomes from genetically responsive and nonresponsive mice. *Biochemical Pharmacology*, **1979**, 28, 111-21	6	27
10	Species differences in the substrate specificity of hepatic cytochrome P-448 from polycyclic hydrocarbon-treated animals. *Biochemical Pharmacology*, **1979**, 28, 217-26	6	78
9	Genetic differences in the metabolic activation of benzo[a]pyrene in mice. Attempts to correlate tumorigenesis with binding of reactive intermediates to DNA and with mutagenesis in vitro. *Pharmacology*, **1979**, 18, 281-93	2.3	29
8	A rapid sensitive assay for glutathione S-epoxidetransferase activity: species differences in the activity of the hepatic enzyme [proceedings]. *Biochemical Society Transactions*, **1979**, 7, 1060-1	5.1	7
7	Induction of aryl hydrocarbon (benzo[a]pyrene) hydroxylase and 2-acetylaminofluorene N-hydroxylase by polycyclic hydrocarbons in regenerating liver from inbred strains of mice. *Biochemical Pharmacology*, **1977**, 26, 1501-5	6	5

6	Genetic differences in the metabolism of carcinogens and in the binding of benzo (a) pyrene metabolites to DNA. *Advances in Enzyme Regulation*, **1976**, 15, 339-62		9
5	Differential induction of murine Ah locus-associated monooxygenase activities in rabbit liver and kidney. *Biochemical Pharmacology*, **1975**, 24, 2111-6	6	40
4	Ethanol protection against hemicholinium toxicity in mice. *Biochemical Pharmacology*, **1975**, 24, 485-8	6	4
3	The effect of pretreating rats with 3-methylcholanthrene upon the enhancement of microsomal aniline hydroxylation by acetone and other agents. *Biochemical Pharmacology*, **1975**, 24, 424-6	6	11
2	Effect of washing the hepatic microsomal fraction in sucrose solutions and in sucrose solution containing EDTA upon the metabolism of foreign compounds. *Biochemical Pharmacology*, **1975**, 24, 1771-6	6	19
1	The effects of catecholamines upon the metabolism of foreign compounds and upon the distribution of perfusate in the isolated liver of the rat. *Biochemical Pharmacology*, **1974**, 23, 3377-84	6	12